fda removes semaglutide shortage list 2025 On February 21, 2025, the announced that semaglutide, the active ingredient in Ozempic and Wegovy, is no longer considered in shortage, signaling an improvement in national supply. As a result, compounding The FDA Wins. The OFA
Description
Table 9

By means of a batch-specific Certificate of Analysis (COA) with a purity percentage of 99%, determined by HPLC and mass spectrometry at an independent laboratory

For detailed conversion math at every dose level, see our tirzepatide dosage chart in units

This shows the impact of medical innovation and the dedication to a healthier lifestyle

For weight management specifically, comparisons should reference the higher 2.4 mg dose of semaglutide (Wegovy) rather than the 1 mg dose used for diabetes

The weight loss labeled Saxenda will not have its generic launch for another 2-3 years, so utilization management will need to be considered